Exelixis Inc. (EXEL)
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Smartest Biotech Stocks to Buy With $50
One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share prices, it's possible to buy shares of quality stocks with $50 -- or less.
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
Biotech leader Exelixis stock is attempting to regain a recent buy point during Monday's stock market rally. The post Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally appeared first on Investor's Business Daily.
Exelixis Growth Continues with Big Money Boosts
Oncology company Exelixis, Inc. (EXEL) growing business, eyeing more.
EXEL or TECH: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day.
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
